Search Results

Astragaloside II 25 mg  | 99.70%

TargetMol

Astragaloside II is an effective MDR reversal agent and may be a potential adjunctive agent for hepatic cancer chemotherapy. Astragaloside II also induces osteogenic activities, differentiation, proliferation, and mineralization, through the bone morphogenetic protein-2/MAPK and Smad1/5/8 pathways.

More Information Supplier Page

Saikosaponin D 25 mg  | 99.09%

TargetMol

Saikosaponin D is a novel SERCA inhibitor by inhibiting NF-κB and STAT3 signaling to protect against acetaminophen-induced hepatotoxicity.

More Information Supplier Page

PKM2-IN-1 2 mg  | 99.90%

TargetMol

PKM2-IN-1 (compound 3k) displays PKM2 inhibitory activity with the IC50 value of 2.95 μM. The IC50 value for PKM1 is 4-5-fold higher than that for PKM2.

More Information Supplier Page

Endoxifen 50 mg  | 99.66%

TargetMol

(E/Z)-Endoxifen is an active metabolite of tamoxifen produced by the sequential action of cytochrome P450 (CYP) isoforms, including CYP2D6. It is a strong anti-estrogen, as it has an approximately 100-fold greater affinity for estrogen receptors than tamoxifen. As the efficient conversion of tamoxifen to endoxifen depends on CYP2D6, polymorphisms in this CYP isoform can impact […]

More Information Supplier Page

Endoxifen 10 mg  | 99.66%

TargetMol

(E/Z)-Endoxifen is an active metabolite of tamoxifen produced by the sequential action of cytochrome P450 (CYP) isoforms, including CYP2D6. It is a strong anti-estrogen, as it has an approximately 100-fold greater affinity for estrogen receptors than tamoxifen. As the efficient conversion of tamoxifen to endoxifen depends on CYP2D6, polymorphisms in this CYP isoform can impact […]

More Information Supplier Page